View in EDS

Preparation of acid-responsive antibubbles from CaCO3-based Pickering emulsions.

Saved in:
Bibliographic Details
Title: Preparation of acid-responsive antibubbles from CaCO3-based Pickering emulsions.
Authors: Zia, Rabia1 (AUTHOR), Poortinga, Albert T.2 (AUTHOR), Nazir, Akmal1,3 (AUTHOR) akmal.nazir@uaeu.ac.ae, Ayyash, Mutamed3 (AUTHOR), van Nostrum, Cornelus F.1 (AUTHOR) C.F.vanNostrum@uu.nl
Source: Journal of Colloid & Interface Science. Dec2023:Part B, Vol. 652, p2054-2065. 12p.
Subjects: Stearic acid, Silica nanoparticles, Methylene blue, Emulsions, Bubbles, Calcium carbonate, Silica fume, Mesoporous silica
Abstract: [Display omitted] Hypothesis: Hydrophobized fumed silica particles were previously reported for producing antibubbles that are quite stable in neutral as well as in acidic media. To produce acid-responsive antibubbles (e.g., for gastric drug delivery), the silica nanoparticles must be replaced by suitable particles, e.g., calcium carbonate (CaCO 3), which can degrade at low pH to release the encapsulated drug. Experiments: Two variants of CaCO 3 -stabilized antibubbles were prepared (by using CaCO 3 particles pre-coated with stearic acid, or by using native CaCO 3 particles in combination with sodium stearoyl lactylate) and drug release was compared with classic antibubbles produced with hydrophobized fumed silica particles. Findings: CaCO 3 particles (pre-coated with stearic acid) can be used to produce stable antibubbles, which provided an entrapment efficiency of a model drug (methylene blue, MB) of around 85%. A burst release of MB (∼60%) from the antibubbles was observed at pH 2 (i.e., the pH of the stomach), which was further increased to 80% during the next 30 min. On the contrary, at neutral pH, about 70% of the drug remained encapsulated for at least 2 h. We further demonstrated that the acidic conditions led to the desorption of CaCO 3 particles from the air–liquid interface resulting in the destabilization of the antibubbles and the release of drug-containing cores. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Colloid & Interface Science is the property of Academic Press Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:[Display omitted] Hypothesis: Hydrophobized fumed silica particles were previously reported for producing antibubbles that are quite stable in neutral as well as in acidic media. To produce acid-responsive antibubbles (e.g., for gastric drug delivery), the silica nanoparticles must be replaced by suitable particles, e.g., calcium carbonate (CaCO 3), which can degrade at low pH to release the encapsulated drug. Experiments: Two variants of CaCO 3 -stabilized antibubbles were prepared (by using CaCO 3 particles pre-coated with stearic acid, or by using native CaCO 3 particles in combination with sodium stearoyl lactylate) and drug release was compared with classic antibubbles produced with hydrophobized fumed silica particles. Findings: CaCO 3 particles (pre-coated with stearic acid) can be used to produce stable antibubbles, which provided an entrapment efficiency of a model drug (methylene blue, MB) of around 85%. A burst release of MB (∼60%) from the antibubbles was observed at pH 2 (i.e., the pH of the stomach), which was further increased to 80% during the next 30 min. On the contrary, at neutral pH, about 70% of the drug remained encapsulated for at least 2 h. We further demonstrated that the acidic conditions led to the desorption of CaCO 3 particles from the air–liquid interface resulting in the destabilization of the antibubbles and the release of drug-containing cores. [ABSTRACT FROM AUTHOR]
ISSN:00219797
DOI:10.1016/j.jcis.2023.09.007